efficacy and safety of oral pioglitazone in treatment of lichen planopilaris

Phase 3

Recruiting

• Conditions: ichen planopilaris.; Lichen planopilaris; L66.1

• Registration Number: IRCT20230415057912N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

a disease that is resistant to treatment. It means that the treatment has been ineffective for at least 6 months.
Newly diagnosed patients who have not yet received treatment.
Patients who have been treated before and whose disease is still active.
Patients who, for any reason, have discontinued any previous medication 1 month before entering the study and have not used any other medication at the time of the study.
Patients between 18 and 50 years old

Exclusion Criteria

Pregnancy or breastfeeding
wbc<3000
platelet<100000
hemoglobin<9
Liver enzymes that are too normal for reference and active liver disease
Positive tests for viral hepatitis
Heart failure
Type 1 diabetes
Allergy to pioglitazone and methotrexate
Bladder cancer
Tissue edema

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ichen Planopilaris Activity Index. Timepoint: Months 0, 2, 4, and 6 after starting the drug. Method of measurement: Handyscope dermatoskope (FotoFinder System GmbH, Bad Brinbach, Germany.